We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

AVGO:NASDAQBroadcom Inc. Analysis

Data as of 2026-06-14 - not real-time

$382.07

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Broadcom (AVGO) is trading at $382.07, which sits below its 20‑day SMA of $418.73 and its 50‑day SMA of $406.45, while the MACD remains in a bearish configuration (‑5.89 vs. signal 2.63) and the RSI is at 41, suggesting short‑term downside pressure. nevertheless, the 30‑day volatility of 62% and a computed beta of 2.15 reflect a highly reactive stock, and the technical trend is still flagged as bullish with a support level near $370 and a DCF‑derived fair value of $197.74 implying a theoretical upside of roughly 36% from current levels.
Fundamentally, AVGO delivered 47.9% revenue growth to $75.5 B, maintains a gross margin of 76% and an operating margin of 49%, and generates robust cash flow ($33.6 B operating, $27.2 B free). The dividend payout ratio of 41% and a 0.68% yield are comfortably supported by cash. Recent analyst upgrades, a “strong‑buy” consensus, and the launch of an AI infrastructure platform with Apollo and Blackstone underscore growth momentum, while the median price target of $525 suggests the market still expects further appreciation.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price below short‑term moving averages
  • Bearish MACD and modest RSI
  • High volatility and beta increasing short‑term risk

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • 48% YoY revenue growth driven by AI and software segments
  • Analyst upgrades and strong consensus “strong‑buy” rating
  • Strategic AI infrastructure partnership expanding addressable market

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustainable dividend with low payout ratio and ample cash flow
  • High ROE (37%) and durable competitive moat in semiconductors and software
  • Long‑term upside potential reflected in median price target of $525

Key Metrics & Analysis

Financial Health

Revenue Growth47.90%
Profit Margin38.85%
P/E Ratio63.7
ROE37.28%
ROA12.12%
Debt/Equity74.02
P/B Ratio20.7
Op. Cash Flow$33.6B
Free Cash Flow$27.2B
Industry P/E36.8

Technical Analysis

TrendBullish
RSI41.4
Support$370.33
Resistance$495.00
MA 20$418.73
MA 50$406.45
MA 200$358.10
MACDBearish
VolumeIncreasing
Fear & Greed Index89.86

Valuation

Fair Value$197.74
Target Price$522.06
Upside/Downside36.64%
GradeOvervalued
TypeGrowth
Dividend Yield0.68%

Risk Assessment

Beta2.15
Volatility62.05%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.